CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Cue Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$16.08−0.63 (-3.77%)
Close on Oct 19, 2026
- Market cap
- $101.96M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-96.7%+1331.3 pts over 5 years
Net margin
-96.9%+1322.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +195.7% | +180.5% | +54.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -67.1% | -121.1% | |
| Return on assets | – | -52.3% | -71.5% | |
| Current ratio | – | 5.36 | 2.74 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | – | -265.5× | |
| Capex to revenue | – | 18.9% | 0.6% | |
| Diluted shares | – | 1M | 3M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cue Biopharma generated $178.62M from operations and spent $2.28M on capital expenditure, dividends and share buybacks. 58% of that went back into the business.
Generated
$178.62M
Used
$2.28M
Capital expenditure$1.33M58%Dividends$00%Share buybacks$950.13K42%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-96.9%
×Asset turnover0.74×
×Equity multiplier1.69×
=Return on equity, FY2025-121.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -96.9% | 0.74× | 1.69× | -121.1% |
| FY2024 | -438.0% | 0.20× | 1.72× | -149.0% |
| FY2023 | -924.1% | 0.07× | 1.49× | -98.7% |
| FY2022 | -4257.8% | 0.01× | 1.33× | -80.8% |
| FY2021 | -295.6% | 0.16× | 1.27× | -61.2% |
| FY2020 | -1419.8% | 0.04× | 1.28× | -67.1% |
| FY2019 | -1061.2% | 0.06× | 1.32× | -82.9% |
| FY2018 | -3411.5% | 0.02× | 1.18× | -81.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$26.60M
- Cash generatingOperating cash flow above zero-$21.69M
- Return on assets improvedROA up on the prior year-66.1% → -82.6%
- Earnings backed by cashOperating cash flow above net income-$21.69M vs -$26.60M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose1.84 → 2.74
- No dilutionShare count did not rise2M → 3M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.15 → 0.85